Literature DB >> 7963714

Cytokine response to respiratory syncytial virus stimulation of human peripheral blood mononuclear cells.

L J Anderson1, C Tsou, C Potter, H L Keyserling, T F Smith, G Ananaba, C R Bangham.   

Abstract

A key impediment to developing respiratory syncytial virus (RSV) vaccines is a lack of understanding of enhanced disease that occurred in children who received a formalin-inactivated RSV (FI-RSV) vaccine. Studies in mice have suggested that the FI-RSV vaccine induces a TH2 and live RSV induces a TH1 memory T cell response. In this study, the cytokine mRNA response of peripheral blood mononuclear cells (PBMC) from adults and children with and without previous RSV infection was characterized using a semiquantitative polymerase chain reaction (PCR). PBMC from 22 subjects previously infected with RSV usually had RSV-specific increases in TH1 cytokine-specific mRNA (interferon-gamma [IFN-gamma] mRNA, 20; interleukin [IL]-2 mRNA, 12; IL-5 mRNA, 6; and IL-4 mRNA, 0). PBMC from RSV antibody-negative children had no RSV-specific increases in IFN-gamma, IL-2, or IL-4 mRNA; 1 of 7 had an increase in IL-5 mRNA. These data indicate that naturally acquired RSV induces a TH1 memory T cell response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963714     DOI: 10.1093/infdis/170.5.1201

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry.

Authors:  K Bendelja; A Gagro; A Bace; R Lokar-Kolbas; V Krsulovic-Hresic; V Drazenovic; G Mlinaric-Galinovic; S Rabatic
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern.

Authors:  M E Waris; C Tsou; D D Erdman; S R Zaki; L J Anderson
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 3.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 4.  Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.

Authors:  J B Domachowske; H F Rosenberg
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Increased number of T cells committed to IL-5 production after respiratory syncytial virus (RSV) infection of human mononuclear cells in vitro.

Authors:  A M Thurau; H J Streckert; C H Rieger; U Schauer
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

6.  Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection.

Authors:  A Srikiatkhachorn; T J Braciale
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 7.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

8.  Functional analysis of antibody responses of feedlot cattle to bovine respiratory syncytial virus following vaccination with mixed vaccines.

Authors:  K West; J Ellis
Journal:  Can J Vet Res       Date:  1997-01       Impact factor: 1.310

9.  Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age.

Authors:  Bessey Geevarghese; Adriana Weinberg
Journal:  Hum Vaccin Immunother       Date:  2014-02-10       Impact factor: 3.452

Review 10.  Respiratory syncytial virus infections in the adult asthmatic--mechanisms of host susceptibility and viral subversion.

Authors:  Blair D Westerly; R Stokes Peebles
Journal:  Immunol Allergy Clin North Am       Date:  2010-09-22       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.